Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

Allyson M. Flower, MD, Rachel Friedmann, DO, Janet Ayello, MS, MT(ASCP), Olivia Rigot, PhD, Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Meghan Sturhahn, RN, MSN, Elana Maryamchik, MD, Yongping Wang, MD, Lynn O'Donnell, PhD, Rolla Abu-Arja, MD, Dean Anthony Lee, MD PhD, Julie-An Talano, MD, Bryon Johnson, PhD, Nancy Bunin, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140834

Published: 2020

Journal Articles

Preliminary Results of a Phase II Study to Determine the Safety of Defibrotide in Children and Adolescents with Sickle Cell Disease-Associated Acute Chest Syndrome (IND 127812)

Jordan Milner, MD, Deborah Friedman, MD, Marise D'Souza, MD MSc, Krishnan Sankaran, MD, Liana Klejmont, Pharm D, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Neida Otero, Jessica C. Hochberg, MD, Adele Brudnicki, MD, Ken R. Cooke, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139617

Published: 2020

Journal Articles

Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism in Patients Receiving G-CSF Mobilized Peripheral Blood Stem Cells (PB-SC) from Related or Unrelated Donors Undergoing CD34 Enrichment with Mononuclear Cell (T cell) Addback in Children, Adolescents, and Adults with Malignant and Nonmalignant Diseases

Jordan Milner, Cydney Nichols, Janet Ayello, MS, MT(ASCP), Karen P. Seiter, MD, Delong Liu, MD PhD, Erin Morris, RN, BSN, Sandra Fabricatore, RN, PNP, MSN, Yaya Chu, PhD, Rosemarie Shaw, Carmella van de Ven, MA, Allyson M. Flower, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-137668

Published: 2020

Journal Articles

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Bryon Johnson, PhD, Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140425

Published: 2020

Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 3963.

https://doi.org/10.1182/blood-2019-128580

Published: 2019

Journal Articles

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Ashley Pinchinat, MD, Neida Otero, Harshini Mahanti, BS, MSCR, Erin Morris, RN, BSN, Adele Brudnicki, MD, Deborah Friedman, MD, Simon Li, MD, Oya Levendoglu-Tugal, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 2443.

https://doi.org/10.1182/blood-2019-130468

Published: 2019

Journal Articles

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 1990.

https://doi.org/10.1182/blood-2019-126757

Published: 2019

Journal Articles

Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD)

Blood (2018) 132 (Supplement 1): 162.

https://doi.org/10.1182/blood-2018-162

Published: 2018

Journal Articles

Promising Results at 1 Year Follow-up Following Familial Haploidentical (FHI) T-Cell Depleted (TCD) with CD34 Enrichment and T-Cell (CD3) Addback Allogeneic Stem Cell Transplantation in Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)

Julie-An Talano, MD, Theodore B Moore, MD, Carolyn A. Keever-Taylor, DPhil, Shalini Shenoy, MD, Mark C. Walters, MD, Susan K Parsons, MD MRP, Allen J Dozor, MD, Deborah Friedman, MD, Qiuhu Shi, PhD, Suzanne Braniecki, PhD, Brenda J. Grossman, MD, Rona Singer Weinberg, PhD, Elliott Vichinsky, MD, Yaya Chu, PhD, Erin Morris, RN, BSN, Sandra Fabricatore, RN, PNP, MSN, Janet Ayello, MS, MT(ASCP), Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 4602.

https://doi.org/10.1182/blood.V130.Suppl_1.4602.4602

Published: 2017

Journal Articles

A Pilot Study of Reduced Toxicity Conditioning (RTC) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism In Patients with Symptomatic Sickle Cell Disease (SCD)

Monica Bhatia, MD, Mark B Geyer, AB, Courtney Baker, RN, MSN, PNP, Erin Morris, RN, BSN, Deirdre Duffy, BS, Diane George, MD, James H Garvin, Jr., MD, PhD, Prakash Satwani, MD, Joseph Schwartz, MD, Sandra Foley, CPNP, Ria Hawks, CPNP, Elana Hamburger-Smilow, CPNP, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 3504.

https://doi.org/10.1182/blood.V116.21.3504.3504

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Preliminary Results of a Phase II Study to Determine the Safety of Defibrotide in Children and Adolescents with Sickle Cell Disease-Associated Acute Chest Syndrome (IND 127812)

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD)

Promising Results at 1 Year Follow-up Following Familial Haploidentical (FHI) T-Cell Depleted (TCD) with CD34 Enrichment and T-Cell (CD3) Addback Allogeneic Stem Cell Transplantation in Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)

A Pilot Study of Reduced Toxicity Conditioning (RTC) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism In Patients with Symptomatic Sickle Cell Disease (SCD)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only